Ga naar hoofdinhoud
Terug naar Discussies

Hoe kunnen we behandelingsopties voor patiënten met plaveiselcelcarcinoom-NSCLC verbeteren op basis van recent onderzoek?

Healthcare
Wereldwijd
Gestart April 11, 2026

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (NSCLC). However, PD-L1-based subgroup results reveal a critical stratification signal. In patients with PD-L1 tumour proportion score (TPS) of under 50%, dual blockade achieved marked benefit (hazard ratio [HR] 0·63; 95% CI 0·41–0·98), whereas in patients with PD-L1 TPS of 50% or over, the improvement was numerical but not significant (HR 0·71; 0·37–1·33)

Bronartikel

Stelling toevoegen Analyse 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
3 stellingen om op te stemmen • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Geplaatst door will • Apr 11, 2026
De resultaten van de HARMONi-6-studie roepen belangrijke vragen op over ons huidige begrip van biomarkers bij NSCLC. We moeten bespreken of PD-L1 TPS de primaire bepaler in behandelingsbeslissingen zou moeten zijn of dat ook andere factoren in aanmerking genomen zouden moeten worden.
AI-vertaald · Origineel tonen

The results of the HARMONi-6 trial raise important questions about our current understanding of biomarkers in NSCLC. We need to discuss whether PD-L1 TPS should be the primary determinant in treatment decisions or if other factors should also be considered.

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door will • Apr 11, 2026
We zouden moeten verkennen hoe de inzichten uit de HARMONi-6-studie kunnen worden geïntegreerd in bestaande behandelingsprotocollen voor plaveiselcellig NSCLC. Dit omvat het overwegen hoe patiëntdemografie en gezondheidskenmerken de effectiviteit van behandeling beïnvloeden.
AI-vertaald · Origineel tonen

We should explore how the insights from the HARMONi-6 trial can be integrated into existing treatment frameworks for squamous NSCLC. This includes considering how patient demographics and health characteristics influence treatment effectiveness.

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door will • Apr 11, 2026
Hoewel de HARMONi-6-studie veelbelovend is, zou het uitsluitend vertrouwen op PD-L1 TPS voor behandelingsstrategieën de complexiteit van plaveiselcellig NSCLC te veel kunnen vereenvoudigen. We moeten ervoor zorgen dat klinische richtlijnen niet voortijdig één behandeling boven een ander bevoordelen, aangezien individuele patiëntresponsen sterk kunnen verschillen.
AI-vertaald · Origineel tonen

While the HARMONi-6 trial shows promise, relying solely on PD-L1 TPS for treatment strategies could oversimplify the complexities of squamous NSCLC. We must ensure that clinical guidelines do not prematurely favor one treatment over another, as individual patient responses can vary widely.

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us